JP2010532372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532372A5 JP2010532372A5 JP2010515112A JP2010515112A JP2010532372A5 JP 2010532372 A5 JP2010532372 A5 JP 2010532372A5 JP 2010515112 A JP2010515112 A JP 2010515112A JP 2010515112 A JP2010515112 A JP 2010515112A JP 2010532372 A5 JP2010532372 A5 JP 2010532372A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- ugt
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 179
- 150000001875 compounds Chemical class 0.000 claims description 140
- 230000004060 metabolic process Effects 0.000 claims description 57
- 230000037361 pathway Effects 0.000 claims description 57
- -1 3-Chloro-2-fluorobenzyl Chemical group 0.000 claims description 55
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 44
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 37
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 24
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 24
- 229960003277 atazanavir Drugs 0.000 claims description 24
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 21
- 229960000311 ritonavir Drugs 0.000 claims description 21
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 21
- 150000001735 carboxylic acids Chemical class 0.000 claims description 20
- 241000282412 Homo Species 0.000 claims description 17
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 12
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- NDCFBPDNHOZORS-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2NCC(C(=O)O)=CC2=C1 NDCFBPDNHOZORS-UHFFFAOYSA-N 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 6
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 6
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 6
- 229940049706 benzodiazepine Drugs 0.000 claims description 6
- 229960002626 clarithromycin Drugs 0.000 claims description 6
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229960003276 erythromycin Drugs 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229930003935 flavonoid Natural products 0.000 claims description 6
- 150000002215 flavonoids Chemical class 0.000 claims description 6
- 235000017173 flavonoids Nutrition 0.000 claims description 6
- 229960001936 indinavir Drugs 0.000 claims description 6
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229960004130 itraconazole Drugs 0.000 claims description 6
- 229960004125 ketoconazole Drugs 0.000 claims description 6
- 229960000884 nelfinavir Drugs 0.000 claims description 6
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 229960001852 saquinavir Drugs 0.000 claims description 6
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- QROPNBKULZRDMD-UHFFFAOYSA-N 7-methoxy-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound N1C=C(C(O)=O)C(=O)C=2C1=CC(OC)=CC=2 QROPNBKULZRDMD-UHFFFAOYSA-N 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 102100034343 Integrase Human genes 0.000 claims description 4
- 108010061833 Integrases Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- DTYLXDLAOLOTKT-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=C1 DTYLXDLAOLOTKT-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 23
- 239000000178 monomer Substances 0.000 claims 5
- 0 CC(C)c1cc(CN(C)C(N[C@@]2([C@@](CN3CCOCC3)C2)C(N[C@](CC[C@](C=Cc2ccccc2)NC(OCc2cnc[s]2)=*)C#Cc2ccccc2)=O)=O)c[s]1 Chemical compound CC(C)c1cc(CN(C)C(N[C@@]2([C@@](CN3CCOCC3)C2)C(N[C@](CC[C@](C=Cc2ccccc2)NC(OCc2cnc[s]2)=*)C#Cc2ccccc2)=O)=O)c[s]1 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94730607P | 2007-06-29 | 2007-06-29 | |
| US60/947,306 | 2007-06-29 | ||
| US4092008P | 2008-03-31 | 2008-03-31 | |
| US61/040,920 | 2008-03-31 | ||
| PCT/US2008/068339 WO2009006199A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and the use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013142322A Division JP5769763B2 (ja) | 2007-06-29 | 2013-07-08 | 治療用組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532372A JP2010532372A (ja) | 2010-10-07 |
| JP2010532372A5 true JP2010532372A5 (cg-RX-API-DMAC7.html) | 2011-07-28 |
| JP5547066B2 JP5547066B2 (ja) | 2014-07-09 |
Family
ID=39831893
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515112A Expired - Fee Related JP5547066B2 (ja) | 2007-06-29 | 2008-06-26 | 治療用組成物およびその使用 |
| JP2013142322A Expired - Fee Related JP5769763B2 (ja) | 2007-06-29 | 2013-07-08 | 治療用組成物およびその使用 |
| JP2015094707A Withdrawn JP2015143278A (ja) | 2007-06-29 | 2015-05-07 | 治療用組成物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013142322A Expired - Fee Related JP5769763B2 (ja) | 2007-06-29 | 2013-07-08 | 治療用組成物およびその使用 |
| JP2015094707A Withdrawn JP2015143278A (ja) | 2007-06-29 | 2015-05-07 | 治療用組成物およびその使用 |
Country Status (19)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20080313A2 (en) * | 2005-12-30 | 2008-11-30 | Gilead Sciences | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP4566670A3 (en) | 2006-07-07 | 2025-08-27 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| SG10201501782UA (en) | 2006-09-12 | 2015-05-28 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| AP3915A (en) * | 2007-02-23 | 2016-11-29 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| EP2167089A1 (en) * | 2007-06-29 | 2010-03-31 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| KR20100040892A (ko) * | 2007-06-29 | 2010-04-21 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| ES2582877T3 (es) * | 2010-04-09 | 2016-09-15 | Bristol-Myers Squibb Holdings Ireland | Formulaciones de sulfato de atazanavir con un efecto de pH mejorado |
| WO2012088178A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| EP3750544B1 (en) | 2011-11-30 | 2025-03-05 | Emory University | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| CA2878699C (en) | 2012-08-03 | 2018-09-11 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| CN107674086B (zh) | 2012-12-21 | 2020-03-31 | 吉利德科学公司 | 多环-氨基甲酰基吡啶酮化合物及其药物用途 |
| PL3252058T3 (pl) | 2013-07-12 | 2021-07-19 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| NO2865735T3 (cg-RX-API-DMAC7.html) | 2013-07-12 | 2018-07-21 | ||
| WO2015120057A1 (en) * | 2014-02-05 | 2015-08-13 | Gilead Sciences, Inc. | Pharmaceutical combinations against co-infection with hiv and tuberculosis |
| NO2717902T3 (cg-RX-API-DMAC7.html) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| HK1249103B (en) | 2015-04-02 | 2020-02-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6544540B2 (en) * | 1998-07-29 | 2003-04-08 | Syngenta Limited | Base-triggered release microcapsules |
| KR100665919B1 (ko) * | 2002-11-20 | 2007-03-08 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도 |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP3287130A1 (en) * | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| HRP20080313A2 (en) * | 2005-12-30 | 2008-11-30 | Gilead Sciences | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP4566670A3 (en) * | 2006-07-07 | 2025-08-27 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| SG10201501782UA (en) * | 2006-09-12 | 2015-05-28 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| KR20100040892A (ko) * | 2007-06-29 | 2010-04-21 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
| EP2167089A1 (en) * | 2007-06-29 | 2010-03-31 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| HRP20151357T1 (hr) * | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 KR KR1020107001981A patent/KR20100040892A/ko not_active Ceased
- 2008-06-26 EA EA200971093A patent/EA200971093A1/ru unknown
- 2008-06-26 AU AU2008270630A patent/AU2008270630B2/en not_active Ceased
- 2008-06-26 SG SG2012046934A patent/SG182229A1/en unknown
- 2008-06-26 AP AP2009005074A patent/AP2965A/xx active
- 2008-06-26 WO PCT/US2008/068339 patent/WO2009006199A1/en not_active Ceased
- 2008-06-26 BR BRPI0813000-0A2A patent/BRPI0813000A2/pt not_active IP Right Cessation
- 2008-06-26 CA CA002692101A patent/CA2692101A1/en not_active Abandoned
- 2008-06-26 AR ARP080102759A patent/AR067183A1/es not_active Application Discontinuation
- 2008-06-26 MX MX2009013829A patent/MX2009013829A/es unknown
- 2008-06-26 NZ NZ582086A patent/NZ582086A/en not_active IP Right Cessation
- 2008-06-26 CN CN201310302662.XA patent/CN103480000A/zh active Pending
- 2008-06-26 JP JP2010515112A patent/JP5547066B2/ja not_active Expired - Fee Related
- 2008-06-26 EP EP08772024A patent/EP2167088A1/en not_active Withdrawn
- 2008-06-26 US US12/147,041 patent/US20090093467A1/en not_active Abandoned
- 2008-06-26 CN CN2008800228167A patent/CN101686972B/zh not_active Expired - Fee Related
- 2008-06-26 TW TW097123983A patent/TW200914011A/zh unknown
- 2008-06-26 US US12/666,991 patent/US20100331331A1/en not_active Abandoned
-
2009
- 2009-12-15 IL IL202744A patent/IL202744A0/en unknown
- 2009-12-21 CO CO09146055A patent/CO6251237A2/es not_active Application Discontinuation
-
2010
- 2010-01-22 EC EC2010009897A patent/ECSP109897A/es unknown
-
2013
- 2013-07-08 JP JP2013142322A patent/JP5769763B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,798 patent/US20140343063A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094707A patent/JP2015143278A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,084 patent/US20170136001A1/en not_active Abandoned